Synthetic Metalloprotease Inhibitors: Small Molecules and Peptides
The matrix metalloproteinases (MMPs) consist of 24 known human zinc proteases with essential roles in breaking down components of the extracellular matrix (ECM). Additional MMP substrates include cytokines, chemokines, growth factors and binding proteins, cell/cell adhesion molecules, and other proteinases. With a few exceptions, MMPs share common structural motifs including a pro-peptide domain, a catalytic domain, a hinge region, and a hemopexin-like domain. Synthesized as pro-enzymes, most MMPs are secreted before conversion to their active form. MMP activities are modulated on several levels including transcription, pro-enzyme activation, or by their endogenous inhibitors, tissue inhibitors of metalloproteinases (TIMPs). A subset of MMPs are associated with membranes and designated as membrane-type metalloproteinases (MT-MMP).
21 results for "Synthetic Metalloprotease Inhibitors Small Molecules and Peptides" in Products
21 results for "Synthetic Metalloprotease Inhibitors Small Molecules and Peptides" in Products
Synthetic Metalloprotease Inhibitors: Small Molecules and Peptides
The matrix metalloproteinases (MMPs) consist of 24 known human zinc proteases with essential roles in breaking down components of the extracellular matrix (ECM). Additional MMP substrates include cytokines, chemokines, growth factors and binding proteins, cell/cell adhesion molecules, and other proteinases. With a few exceptions, MMPs share common structural motifs including a pro-peptide domain, a catalytic domain, a hinge region, and a hemopexin-like domain. Synthesized as pro-enzymes, most MMPs are secreted before conversion to their active form. MMP activities are modulated on several levels including transcription, pro-enzyme activation, or by their endogenous inhibitors, tissue inhibitors of metalloproteinases (TIMPs). A subset of MMPs are associated with membranes and designated as membrane-type metalloproteinases (MT-MMP).
Broad-spectrum MMP inhibitor; tetracycline derivative
| Chemical Name: | (4S,4aR,5S,5aR,6R,12aS)-4-(Dimethylamino)- 3,5,10,12,12a-pentahydroxy- 6-methyl- 1,11-dioxo- 1,4,4a,5,5a,6,11,12a-octahydrotetracene- 2-carboxamide hydrochloride hemiethanolate hemihydrate |
| Purity: | ≥92% (HPLC) |
Selective ADAM10 metalloprotease inhibitor
| Chemical Name: | (2R)-N-[(1S)-2,2-Dimethyl-1-[(methylamino)carbonyl]propyl]-2-[(1S)-1-(N-hydroxyformamido)ethyl]-5-phenylpentanamide |
| Purity: | ≥98% (HPLC) |
Broad spectrum MMP inhibitor
| Alternate Names: | BB 2516,Marimistat |
| Chemical Name: | (2S,3R)-N4-[(1S)-2,2-Dimethyl-1-[(methylamino)carbonyl]propyl]-N1,2-dihydroxy-3-(2-methylpropyl)butanediamide |
| Purity: | ≥99% (HPLC) |
Broad spectrum MMP inhibitor
| Alternate Names: | Galardin,Ilomastat |
| Chemical Name: | (2R)-N4-Hydroxy-N1-[(1S)-1-(1H-indol-3-ylmethyl)-2-(methylamino)-2-oxoethyl]-2-(2-methylpropyl)butanediamide |
| Purity: | ≥95% (HPLC) |
Potent, broad spectrum MMP inhibitor
| Alternate Names: | BB-94 |
| Chemical Name: | (2R,3S)-N4-Hydroxy-N1-[(1S)-2-(methylamino)-2-oxo-1-(phenylmethyl)ethyl]-2-(2-methylpropyl)-3-[(2-thienylthio)methyl]butanediamide |
| Purity: | ≥99% (HPLC) |
ADAM-17 (TACE) and MMP inhibitor
| Chemical Name: | N-[(2R)-2-[2-(Hydroxyamino)-2-oxoethyl]-4-methyl-1-oxopentyl]-3-methyl-L-valyl-N-(2-aminoethyl)-L-alaninamide |
| Purity: | ≥95% (HPLC) |
Potent ADAM10 and ADAM17 inhibitor
| Chemical Name: | Phenylmethyl N-[(5S)-5-[[(2R,3S)-3-(formylhydroxyamino)-2-(2-methylpropyl)-1-oxohexyl]amino]-6-oxo-6-(2-thiazolylamino)hexyl]carbamate |
| Purity: | ≥98% (HPLC) |
Potent and selective inhibitor of MMP-13
| Chemical Name: | N-[2-[4-[[[2-[(Hydroxyamino)carbonyl]-4,6-dimethylphenyl](phenylmethyl)amino]sulfonyl]phenoxy]ethyl]-2-benzofurancarboxamide |
| Purity: | ≥99% (HPLC) |
Pro-MMP9 activation inhibitor
| Chemical Name: | N-[2-[(2-Methoxyphenyl)amino]-4'-methyl[4,5'-bithiazol]-2'-yl]acetamide |
| Purity: | ≥98% (HPLC) |
Histone deacetylase inhibitor
| Chemical Name: | 3,4-Dichloro-N-(1-methylbutyl)benzamide |
| Purity: | ≥99% (HPLC) |
ADAM-17 (TACE) and MMP inhibitor
| Alternate Names: | TNF-α processing inhibitor-0 |
| Chemical Name: | N-[(2R)-2-[2-(Hydroxyamino)-2-oxoethyl]-4-methyl-1-oxopentyl]-3-(2-naphthalenyl)-L-alanyl-L-alaninamide |
| Purity: | ≥95% (HPLC) |
Adam 17 (TACE) and MMP inhibitor; orally bioavailable
| Chemical Name: | (3S)-4-[[4-(2-Butyn-1-yloxy)phenyl]sulfonyl]-N-hydroxy-2,2-dimethyl-3-thiomorpholinecarboxamide |
| Purity: | ≥98% (HPLC) |
ADAM-17 (TACE) and MMP inhibitor
| Chemical Name: | N-[(2R)-2-[2-(Hydroxyamino)-2-oxoethyl]-4-methyl-1-oxopentyl]-3-(2-naphthalenyl)--alanyl-L-alaninamide |
| Purity: | ≥95% (HPLC) |
Broad spectrum MMP inhibitor
| Chemical Name: | N-[(4'-Bromo[1,1'-biphenyl]-4-yl)sulfonyl]-L-valine |
| Purity: | ≥99% (HPLC) |
Potent and selective BMP-1 (PCP) inhibitor
| Chemical Name: | 3-(Aminocarbonyl)-β-(3-cyclohexylpropyl)-N-hydroxy-1,2,4-oxadiazole-5-propanamide |
| Purity: | ≥99% (HPLC) |
Inhibitor of MMP-2
| Chemical Name: | (R)-N-Hydroxy-2-(N-isopropoxybiphenyl-4-ylsulfonamido)-3-methylbutanamide |
| Purity: | ≥99% (HPLC) |
Selective inhibitor of MMP-13
| Chemical Name: | N-[4-(4-Morpholinyl)butyl]-2-benzofurancarboxamide hydrochloride |
| Purity: | ≥98% (HPLC) |
Highly selective MMP-3 and MMP-12 inhibitor
| Chemical Name: | (βR)-β-[[[(1S)-1-[[[(1S)-2-Methoxy-1-phenylethyl]amino]carbonyl]-2,2-dimethylpropyl]amino]carbonyl]-2-methyl-[1,1'-biphenyl]-4-hexanoic acid |
| Purity: | ≥95% (HPLC) |
High affinity and selective MMP2 inhibitor
| Chemical Name: | 2-[[(4-Phenoxyphenyl)sulfonyl]methyl]thiirane |
| Purity: | ≥98% (HPLC) |
Potent MMP inhibitor
| Alternate Names: | SC 78080 |
| Chemical Name: | N-Hydroxy-1-(2-methoxyethyl)-4-[4-[4-(trifluoromethoxy)phenoxy]phenyl]sulfonyl]-4-piperidinecarboxamide hydrochloride |
| Purity: | ≥98% (HPLC) |
Antibiotic. Displays neuroprotective effects
| Chemical Name: | [4S-(4α,4aα,5aα,12aα)]-4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a,tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide |
| Purity: | ≥98% (HPLC) |
